Drug Trial Radar · NCT05084053
A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Jan 19, 2022
Primary completion
Oct 28, 2025
Study completion May 29, 2026
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to check for side effects from TAK-771, and to check how well TAK-771 controls symptoms in Japanese participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) The participants will be treated with TAK-771 for 45 months as a maximum. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug (every 2, 3, or 4 weeks).
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Multifocal Motor Neuropathy (MMN)
Interventions
TAK-771Drug
Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Epoch 1: Percentage of Participants With CIDP Who Experienced RelapseTime frame: Epoch 1: Baseline up to 6 months
- Epoch 1: Change From Baseline in Maximum Grip Strength in the More Affected Hand in Participants With MMNTime frame: Epoch 1: Baseline up to 6 months
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Chiba University Hospital
Chiba, Japan
Kyushu University Hospital
Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Japan
Kumamoto University Hospital
Kumamoto, Japan
Higashimatsuyama Municipal Hospital
Saitama, Japan
Tokushima University Hospital
Tokushima, Japan
Toyama University Hospital
Toyama, Japan
Aichi Medical University Hospital
Nagakute, Aichi-ken, Japan
Chubu Rosai Hospital
Nagoya, Aichi-ken, Japan
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Asahikawa Medical Center
Asahikawa, Hokkaido, Japan
Kansai Rosai Hospital
Amagasaki, Hyōgo, Japan
Hyogo College of Medicine Hospital
Nishinomiya, Hyōgo, Japan
St.Marianna University School of Medicine Hospital
Kawasaki, Kanagawa, Japan
Tohoku Medical and Pharmaceutical University Hospital
Sendai, Miyagi, Japan
Nara Medical University Hospital
Kashihara, Nara, Japan
Shiga University of Medical Science Hospital
Ōtsu, Shiga, Japan
Tokushima National Hospital
Yoshinogawa, Tokushima, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Toho University Omori Medical Center
Ōta-ku, Tokyo, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, Japan
Yamaguchi University Hospital
Ube, Yamaguchi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.